Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma

MT Newswires Live09-30

Calidi Biotherapeutics (CLDI) said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses.

A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the Northwestern University, Calidi said.

The study will evaluate the safety of giving multiple doses of CLD-101 to patients with newly diagnosed high-grade glioma, according to the company.

Shares of Calidi were down 4% in recent Monday premarket activity.

Price: 1.1600, Change: -0.05, Percent Change: -4.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471800868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471800868","market":"us","top_or_hot":-1,"title":"Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma","media":"MT Newswires Live","content":"<html><body><p> Calidi Biotherapeutics (CLDI) said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses.</p><p>A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the Northwestern University, Calidi said.</p><p>The study will evaluate the safety of giving multiple doses of CLD-101 to patients with newly diagnosed high-grade glioma, according to the company.</p><p>Shares of Calidi were down 4% in recent Monday premarket activity.</p><p>Price: 1.1600, Change: -0.05, Percent Change: -4.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Calidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalidi Biotherapeutics Says FDA Clears Phase 1b/2 Trial of CLD-101 in High-Grade Glioma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 21:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Calidi Biotherapeutics (CLDI) said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDI","symbol_name":"CALIDI BIOTHERAPEUTICS INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2471800868","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471800868","pubTimestamp":1727701337,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Calidi Biotherapeutics  said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses.A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the Northwestern University, Calidi said.The study will evaluate the safety of giving multiple doses of CLD-101 to patients with newly diagnosed high-grade glioma, according to the company.Shares of Calidi were down 4% in recent Monday premarket activity.Price: 1.1600, Change: -0.05, Percent Change: -4.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDI":"CALIDI BIOTHERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Calidi Biotherapeutics表示FDA批准CLD-101治疗高级别神经胶质瘤的1b/2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDI":0.9},"content_text":"Calidi Biotherapeutics (CLDI) said Monday that the US Food and Drug Administration has cleared Northwestern University's investigational new drug application for the company's CLD-101 therapy, which uses stem cells to deliver engineered oncolytic adenoviruses.A phase 1b/2 trial of the investigational treatment is expected to begin late this year at the Northwestern University, Calidi said.The study will evaluate the safety of giving multiple doses of CLD-101 to patients with newly diagnosed high-grade glioma, according to the company.Shares of Calidi were down 4% in recent Monday premarket activity.Price: 1.1600, Change: -0.05, Percent Change: -4.13","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471800868"}